Entries by CAPTIS

Bayer to buy remaining stake in BlueRock Therapeutics

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m), The post Bayer to buy remaining stake in BlueRock Therapeutics appeared first on Pharmaceutical Business review.

Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with The post Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint appeared first on Pharmaceutical Business review.

Ontario provides access to Biktarvy for treatment of HIV

“To help support the long-term health of people living with HIV, it is ideal that treatment regimens deliver both durable viral suppression and a demonstrated tolerability profile,” said The post Ontario provides access to Biktarvy for treatment of HIV appeared first on Pharmaceutical Business review.